Evidence map›Paper›PMID 41978231›Full record

Trial reportJournal of neuroendocrinology2026

The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [

Johannes Hofland, Chiara Maria Grana, Martin O Weickert, Andrew R Moore, Tahir Shah, Vineet Prakash, Agnieszka Kolasińska-Ćwikła, Wouter W de Herder, Francesca Spada, Lingfei Xu and 3 more

Abstract readMulticenter StudyClinical Trial, Phase IV
In one paragraph

Trial report in Journal of neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Johannes HoflandDepartment of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-0679-6209
Chiara Maria GranaRadiometabolic Therapy Unit, Division of Nuclear Medicine, European Institute of Oncology (IEO), IRCCS, Milan, Italy.ORCID https://orcid.org/0000-0002-3808-2174
Martin O WeickertThe ARDEN NET Centre, ENETS Centre of Excellence, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.ORCID https://orcid.org/0000-0002-4070-8164
Andrew R MooreLiverpool University Hospitals NHS Foundation Trust, Liverpool, UK.ORCID https://orcid.org/0000-0001-7680-998X
Tahir ShahUniversity Hospital Birmingham NHS Foundation Trust, Birmingham, UK.ORCID https://orcid.org/0000-0002-0420-0304
Vineet PrakashRoyal Surrey County NHS Foundation Trust, Surrey, UK.ORCID https://orcid.org/0009-0007-9438-1666
Agnieszka Kolasińska-ĆwikłaMaria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.ORCID https://orcid.org/0000-0002-4034-0267
Wouter W de HerderDepartment of Internal Medicine, Section of Endocrinology, ENETS Center of Excellence, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-1463-5165
Francesca SpadaDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Milan, Italy.ORCID https://orcid.org/0000-0003-3642-0798
Lingfei XuNovartis Pharmaceuticals Corp, East Hanover, New Jersey, USA.
Ramon FiteNovartis Pharma AG, Barcelona, Spain.
Yuan WuNovartis Pharma AG, Basel, Switzerland.ORCID https://orcid.org/0009-0005-3340-6554
Jarosław B ĆwikłaUniversity of Warmia and Mazury, Olsztyn, Poland.ORCID https://orcid.org/0000-0001-5147-4167

Funding

Advanced Accelerator Applications, a Novartis company
6 · The paper itself

Abstract

A post-authorisation safety study (PASS) was conducted to assess the impact of LysaKare (2.5% Lysine-Arginine solution) on serum potassium concentrations and its safety/tolerability profile in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET) eligible for

Indexed as

Intestinal NeoplasmsLysineNeuroendocrine TumorsOrganometallic CompoundsPancreatic NeoplasmsPotassiumStomach NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedOctreotidelutetium Lu 177 dotatateLysineOctreotideOrganometallic CompoundsPotassium177Lu‐DOTATATEHyperkalaemiaLysaKare

Identifiers

PMID41978231
PMCPMC13077017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.